STAAR Surgical Company STAA

Healthcare stocks were edging higher premarket Friday, with the State Street Health Care Select Sect

Investing.com -- STAAR Surgical Company (NASDAQ:STAA) shares rose as much as 2% in after-hours trading Thursday following the company's announcement of a $50 million share repurchase program authorized by its Board of Directors.

LAKE FOREST, Calif., September 24, 2026--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors, at a regularly scheduled meeting, authorized a share repurchase program under which the Company may repurchase up to $50 million of its outstanding common stock.

STAAR Surgical recently reported quarterly net sales of US$93.5 million, an increase of 111% year over year, driven largely by China where revenue more than doubled to US$52.3 million and helped swing the company to US$8.1 million in net income from a loss a year earlier. Alongside this earnings rebound, STAAR strengthened its leadership bench by appointing former CEO David Bailey as Chief Commercial Officer and Ben Park, Ph.D., as Chief Technology Officer, signaling a focus on accelerating...

Executive Changes Reframe STAAR Surgical After Turnaround Results STAAR Surgical (STAA) reported a sharp business turnaround, with net sales rising 111% year over year and net income reaching $8.1 million, helped by China now contributing more than half of revenue. That backdrop sets the stage for two fresh executive appointments at the ophthalmic device producer. These moves could shape how the recent performance is translated into longer term commercial and product decisions. On the market...

On August 12, STAAR Surgical (NASDAQ:STAA) reported results for the quarter ended July 3 that flipped the script from a year earlier. Net sales jumped 111% year over year to $93.5 million, and the company that lost money in the same quarter of 2025 turned in $8.1 million of net income instead. It is the […]

David Bailey has rejoined STAAR after participating in the successful campaign to block Alcon’s takeover of the company.

LAKE FOREST, Calif., September 10, 2026--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today released a new report entitled The Future of Refractive Surgery, the first comprehensive global market analysis showing a consistent, multi-market migration toward implantable lens correction driven by durable tailwinds on the demand and clinical sides of the market.

LAKE FOREST, Calif., September 09, 2026--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of David Bailey as Chief Commercial Officer. Mr. Bailey will join STAAR's executive committee and report to Warren Foust, President and Chief Executive Officer.

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

LAKE FOREST, Calif., September 02, 2026--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Ben Park, Ph.D., as Chief Technology Officer. Dr. Park will join STAAR's Executive Committee and report to Warren Foust, President and Chief Executive Officer.

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.

Check out the companies making headlines this week: